Superworth

Soligenix EPS SNGX

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$1.27
Latest quarter, Q2 FY26
−$0.12
Fiscal year 2025
−$2.66

Soligenix's earnings per share was −$1.27 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.12.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$2.66n/a
FY2024−$6.19n/a
FY2023−$14.68n/a
FY2022−$76.80n/a
FY2021−$74.40n/a
FY2020−$158.40n/a
FY2019−$117.60n/a
FY2018−$177.60n/a
FY2017−$283.20n/a
FY2016−$324.00n/a
FY2015−$1104.00n/a
FY2014−$840.00n/a
FY2013−$1608.00n/a
FY2012−$912.00n/a
FY2011−$528.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.12n/a−$1.27
Q1 FY26−$0.28n/a−$1.97
Q4 FY25−$0.29n/a−$2.66
Q3 FY25−$0.58n/a−$3.56
Q2 FY25−$0.82n/a−$3.76
Q1 FY25−$0.97n/a−$4.25
Q4 FY24−$1.19n/a−$6.19
Q3 FY24−$0.78n/a−$7.80
Q2 FY24−$1.31n/a−$9.58
Q1 FY24−$2.91n/a−$11.83
Q4 FY23−$2.80n/a−$14.68
Q3 FY23−$2.56n/a−$32.68

Against its peers

Companies in Drug Manufacturers - General nearest Soligenix's size, closest first, today.

CompanyEPS, 12 monthsGrowth
SNGXSoligenix−$1.27
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Soligenix

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.